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Abstract – Targeted molecular therapies (TMT) represent 
new perspectives in cancer treatment, fighting against the 
specific characteristic of the investigated tumor. 
Antiangiogenic therapy represents a specific TMT and its 
role is to stop the angiogenesis of the tumor, the process 
of forming new blood vessels; hence, to stop tumor 
growth. Proper control algorithms for tumor growth 
control with angiogenic inhibition are analyzed in the 
current article in order to find optimal therapeutic 
protocols. Two slightly different approaches are 
compared: nonlinear control by exact linearization with 
path tracking control, and linear control by working point 
linearization with set point control. The control strategies 
are compared in terms of the characteristics of the input 
signal (the inhibitor, drug intake) that is crucial if the 
therapy will be put into practice. 
 
Keywords:  flat control, exact linearization, path tracking 
control, tumor growth control, angiogenic 
inhibition. 
 
 
I. INTRODUCTION 
 
Cancer is in the front line of lethal illnesses which demands 
the highest number of human lives in modern societies. 
According to statistics of the European Union, 1.3 million 
people of the European Union were estimated to die from 
cancer in 2011, [1]. Consequently, the treatment is in focus 
of research even in interdisciplinary areas. In this paper we 
apply novel results of nonlinear control theory to a tumor 
growth model, in order to give therapeutic protocols for a 
special type of antitumor therapy, the antiangiogenic 
therapy. The resulting controller is compared to a linear 
control strategy created previously by the authors [2]. 
 
Conventional cancer fighting therapies (like chemotherapy, 
radiotherapy) have general attack points (for example 
chemotherapy works by killing rapidly dividing cells), so 
these treatments have a lot of side effects and affect the 
whole body. In addition, tumor cells can become resistant 
towards the drug used in chemotherapy, which makes the 
usage of new drugs necessary. 
 
However, targeted molecular therapies (TMTs) fight 
specifically against different cancer mechanisms, so these 
treatments can be more effective and have limited side 
effects. A promising field in TMTs is antiangiogenic 
therapy, which had come up in the last decade [3, 4]. "Anti-
angiogenesis is a form of targeted therapy that uses drugs 
or other substances to stop tumors from making new blood 
vessels. Without a blood supply, tumors can't grow" [5]. 
Contrary to conventional treatments, if antiangiogenic 
therapy is used, tumor cells can not become resistant 
towards the antiangiogenic drugs (this is achieved by 
antiangiogenic therapy if it is directed against the tumor 
supplying blood vessels) [6] and antiangiogenic therapy 
can be used with nontoxic concentrations [7]. 
 
Clinical aspects of angiogenic inhibition are discussed 
more detailed in [6, 8]. In [9] a model for tumor growth 
under angiogenic inhibition was developed, and it was 
validated using experiments on mice with lungs cancer (the 
Lewis lung carcinoma). Optimal bang-bang control was 
designed on a simplified model in [10]. Antiangiogenic 
therapy combined with radiotherapy was discussed in [11]. 
Application of linear control theory was investigated in 
[12, 13] for a simplified model. Linear control synthesis 
was worked out in [2, 14, 15] for the model used in this 
paper, while nonlinear control was investigated in [16]. The 
results of [2] and this paper are compared, and it is shown 
that nonlinear control by flat control yields much better 
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input signal characteristics from physiological point of 
view than the results with linear control. 
 
The paper is organized as follows. In Section II, the 
biomedical background of the therapy is reviewed, and the 
nonlinear tumor growth model is examined in Section III. 
After checking the controllability of the model, flat control 
and path tracking control is applied in Section IV. Working 
point based linearization and linear control strategy is 
applied in Section V. The two control strategies are 
compared based on simulations in Section VI. The paper 
ends with the conclusion in Section VII. 
 
 
II. BIOMEDICAL BACKGROUND OF 
ANTIANGIGENIC THERAPY 
 
Rapidly dividing tumor cells need lots of oxygen. When 
proliferation begins, small sized tumor can pick up oxygen 
from near capillaries. After a certain size (1-2 mm 
diameter) tumor development stops, because a part of the 
tumor gets too far from capillaries and cannot pick up 
enough oxygen. Tumor needs own blood vessels - the 
process of forming new blood vessels is called 
angiogenesis [17]. Angiogenesis occurs normally in the 
human body at specific times; in adults it is a relatively 
infrequent event. In such cases, angiogenesis starts due to 
typical molecular triggers and ends when the necessary 
processes are completed. Tumors can break through this 
precise control, and by stimulating angiogenesis, new 
blood vessels are formed to feed the tumor cells. This 
process is called tumor indicated angiogenesis. The usage 
of angiogenic inhibitors blocks this process, and can even 
eliminate already existing blood vessels at the tumorous 
areas. However, by antiangiogenic therapy tumors cannot 
be totally eliminated, since angiogenic inhibition acts only 
on the vascular system. 
 
In the next section, we discuss a nonlinear model, that 
describes the dynamics of angiogenic inhibition and tumor 
indicated angiogenesis. 
 
 
III. NONLINEAR TUMOR GROWTH MODEL 
 
The model of tumor growth under angiogenic inhibition 
was worked out in [9]. The model structure is based on a 
priori knowledge, and the parameters were identified based 
on experiments. In this article the model used for tumor 
growth possesses three state variables: 
• x1 is the tumor volume in mm3; 
• x2 is the endothelial volume in mm3; 
• x3 is the inhibitor serum level in mg/kg. 
The input (u) of the system is the inhibitor intake in 
mg/kg/day, and the output (y) is the tumor volume. The 
dynamics is described as follows: 
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The first two equations are the same as in [9], while the 
third equation is the pharmacokinetic model of the 
inhibitor, appeared in this form in [2]. The parameters in 
the model are λ1 = 0.192 day-1, b = 5.85 day-1, d = 0.00873 
day-1mm-2/3, e = 0.66 day-1mg/kg and λ3 = 1.3 day-1 acquired 
from [9]. 
 
The equations of the dynamic system may be rewritten in 
the following form: 
 
( ) ( )
( )xhy
uxgxfx
=
+=&  (5) 
(6) 
 
where 
 
( )
⎥⎥
⎥⎥
⎥⎥
⎥⎥
⎦
⎤
⎢⎢
⎢⎢
⎢⎢
⎢⎢
⎣
⎡
−
−−
⎟⎟⎠
⎞
⎜⎜⎝
⎛−
=
33
322
32
11
2
1
1
x
xexxdxbx
x
xln
xf /
λ
λ
 
(7) 
 
represents the drift vector field with 
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representing the control vector field, and 
 
( ) 1xxh =  (9) 
 
representing the output of the system. It can be easily 
verified that these equations define a nonlinear, but input 
affine model [16]. 
 
Since in this paper the model is used for control synthesis, 
the analysis of the controllability of the system is required. 
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The nonlinear system has a drift vector field f and a control 
vector field g. Let: 
 
     { }g=0Δ  (10) 
 
denote an initial distribution composed of the control 
vector field. According to [18], the nonlinear system is 
controllable if it satisfies the Lie Algebra Rank Condition, 
so the distribution Δ0 expanded with the Lie brackets [f,g] 
and [f,[f,g]] is involutive. Involutivity is checked by 
handling the expanded distribution as a matrix and 
examining its rank. If this matrix is full rank, then the 
distribution is involutive. In our case, the Lie bracket of the 
drift and the control vector fields is: 
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The Lie bracket of f and [f,g] is: 
 
 
 
[ ][ ] ( )
⎥⎥
⎥
⎦
⎤
⎢⎢
⎢
⎣
⎡
+
−
=
2
3
321
11
λ
λ
λ
xbxe
x
g,f,f  (12) 
 
while the distribution Δ0 expanded with [f,g] and [f,[f,g]] is: 
 [ ] [ ][ ]{ }
( )
⎥⎥
⎥
⎦
⎤
⎢⎢
⎢
⎣
⎡
+
−
=
=
2
33
3212
11
1
0
00
λλ
λ
λ
Δ
xbxeex
x
g,f,f,g,f,g
 (13) 
 
which has full rank if x1 ≠ 0 and x2 ≠ 0, so the nonlinear 
system is controllable if the system is not in the state x1 = 0 
or x2 = 0. Since x1 = 0 means there is no tumor, this case is 
physiologically irrelevant, while if x2 = 0 state is reached, 
the therapy can be switched to a constant dose. This 
constant dose may be calculated from the steady-state 
equations of the model [2]. 
 
 
IV. FEEDBACK LINEARIZATION AND PATH 
TRACKING CONTROL 
 
In this section feedback linearization is applied in order to 
get a representation of the nonlinear system with state 
variables z and input ν that acts like a linear system, i.e. a 
system of serially coupled integrators [16]. In order to do 
so, we choose the first variable z1 as the output of the 
system, i.e. z1 = y, thus z1 = h(x), and look for the 
derivatives of the output. The first and higher order 
derivatives of the output y are: 
 
( ) ( )uxhLxhLy gf +=&  (14) 
( ) ( ) ( ) +++= uxhLLuxhLLxhLy gffgf2&&
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where Lαβ(x) denotes the Lie derivative of β along α, 
expressed in local coordinates as: 
 
( ) αββα xxL ∂
∂= . (17) 
 
LγLαβ(x) is the Lie derivative of Lαβ(x) along γ, while 
multiple derivation along the same vector field is denoted 
by the appropriate powers, i.e. 
 
      
( ) ( ))...))xL(...(L(LxL
k
k ββ αααα 44 344 21= . (18) 
 
 
The system defined by (14)-(16) is analogous to a series of 
integrators if the input u of the original system appears only 
in the highest order derivative of the output. The order of 
the derivative of a given output where the input appears 
explicitly is called the relative degree of the output [18]. 
Hence, the representation in (14)-(16) is a series of 
integrators if the relative degree of y is maximal. 
 
The relative degree of an output of a system is r, if: 
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holds [18]. If the system has maximal relative degree then 
it can be linearized through static nonlinear state feedback, 
thus no internal state variables are required in the feedback. 
In this particular case: 
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thus the relative degree of the output is r = 3 if x1 ≠ 0. Since 
the x1 = 0 case is already excluded, the output has maximal 
relative degree in all cases. 
 
Feedback linearization is done by transforming the system 
to a series of integrators, thus the behavior of the zi, i ∈  
{1,2,3} transformed system variables will be defined by the 
equations: 
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where ν is the input of the transformed system and y is the 
output of the original and the transformed system as well. 
The transformed system variables may be acquired by 
introducing the following coordinate transformation: 
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The derivatives of the transformed variables are: 
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Since our aim is to handle the system as a series of 
integrators in the zi variables, the input acts on ν = z3, and 
the nonlinear feedback is used to calculate the input of the 
original system as: 
 ( )
( )xb
xavu −=  (34) 
 
The expressions for a(x) and b(x) are: 
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Applying the coordinate transformation defined by (28)-
(30), and the nonlinear feedback (34), the resulting system 
with state variables {z1,z2,z3}, input ν and output y can be 
handled as a system composed of three serially connected 
integrators defined by (14)-(16) that is a linear system, thus 
linear controller design may be applied. 
 
 
Fig. 1. Control Architecture of the path tracking with exact linearization. 
 
The control strategy applied for the exact linearization case 
is path tracking [18]. Suppose that the desired evolution of 
tumor volume is given in advance, thus we have a 
reference signal x1,ref = yref, and its derivatives up to third 
order are also known. The reference signals are given as a 
set of vectors { }refrefrefref y,y,y,y &&&&&& . The control law applied 
is: 
 ( ) ( ) ( )yykyykyykyv refrefrefref −+−+−+= 123 &&&&&&&&&  (37) 
 
with K = [k3 k2 k1] being the coefficients of a Hurwitz 
polynomial describing the tracking error dynamics. Since 
applying the coordinate transformation defined by (28)-
(30) results in a series of integrators, the output y and its 
derivatives are explicitly given by 1zy = , 2zy =& , 3zy =&& . 
Hence: 
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( ) ( ) ( )112233 zykzykzykyv refrefrefref −+−+−+= &&&&&&&  (38) 
 
 
The control architecture is depicted in Fig. 1. The inputs of 
the controller are the reference signal and its derivatives, 
and the states of the nonlinear model. The output of the 
controller is the actuator's signal, e.g. the level of the drug 
administration rate. The controller consists of the 
coordinate transformation, the control law and the 
nonlinear feedback. 
 
 
V. WORKING POINT LINEARIZATION AND SET 
POINT CONTROL 
 
In case of this approach, the system is linearized in a 
working point, and the system dynamics is defined with the 
first order terms of the Taylor polynomial of the nonlinear 
system, i.e. 
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The working point is chosen to be in a steady-state, with 
the less amount of inhibitor possible as: 
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The chosen working point is x10 = 100 mm3, that is 
desirably low among the possible tumor volumes. The 
applied control law was Linear Quadratic (LQ) control, 
with a polynomial observer, i.e. a state-feedback that 
minimizes: 
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with the design parameters chosen as: 
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i.e. it is an expensive control, and the energy of x1 and x3 is 
also minimized. This is satisfied by a state-feedback u = - 
Kx, where K = R-1BTP, and P is the solution of the Control 
Algebraic Ricatti Equation (CARE): 
 
  0
1 =+−+ − QPBPBRPAPA TT . (48) 
 
The applied observer is a polynomial observer, with: 
 
HuGyxˆFxˆ ++=& , (49) 
 
and the parameters are chosen to guarantee predefined 
estimation error characteristics, i.e. G is designed as a pole-
placement for the fictive system AT, CT with predefined 
observer poles, and F = A – GC, H = B. The observer poles 
are chosen to be five times faster than the poles of the 
closed loop system resulted with the previously defined 
control law. 
 
Since we apply set point control here (we control the 
system to the zero state) and thus the initial error signal can 
be very large, this may result in large input signal. Large 
input signal however is physiologically meaningless, so we 
need to put saturation at the output of the controller. The 
resulting control architecture is depicted on Fig. 2.  
 
 
Fig. 2. The architecture of set point controller designed for the linearized 
model. 
 
 
VI. COMPARISION OF CONTROL STRATEGIES 
THROUGH SIMULATION RESULTS 
 
First we show simulation result for the flat control with 
path tracking control law defined in Section IV. It is 
assumed, that the states of the nonlinear system are 
 
 
118 
available. Note that this is not the case in the reality, since 
the measurement of the endothelial volume and the 
inhibitor serum level is expensive and difficult; however, 
the solution of this problem (e.g. application of a nonlinear 
state observer) is the subject of further research. The 
reference signal and its derivatives are: 
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The initial tumor volume x1,0 is chosen as the maximal 
tumor volume that can be reached with 0 input, numerically 
x1,0 = 17347 mm3. The Ttreat is the time constant of the 
desired exponential characteristics of tumor elimination, 
chosen to be Ttreat = 6 days in the simulations. The vector 
K, defining the path tracking error dynamics, is chosen as: 
 [ ]811=K  (54) 
 
This polynomial is Hurwitz, with roots: 
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The original tumor model was initiated at its equilibrium 
state without input, where the tumor volume and 
endothelial volume are equal and their value is x1,0 = 17347 
mm3. The time swap of the simulation was 100 days. The 
evolution of the tumor volume during the 100 days of 
treatment is shown on Fig. 3, while the administered 
inhibitor is shown on Fig. 4. The tumor volume dropped 
drastically during the treatment, it reached 63 mm3 in 40 
days, 2 mm3 in 90 days, while the inhibitor injection rate 
stayed considerably low during the whole period of the 
treatment. The inhibitor injection was 28 mg/kg/day at the 
40th day of the treatment, reached its maximum of 28.72 
mg/kg/day at the 53rd day of the treatment, and it was 15.88 
mg/kg/day at the 90th day of the treatment, close to the 
value of 15.0682 mg/kg/day, that is the inhibitor injection 
rate needed to maintain the tumor volume close to 0 mm3 
[2]. The total amount of inhibitor used during the 100 days 
treatment period is 2253 mg/kg. 
 
 
Fig. 3. The evolution of the tumor volume with flat control and path 
tracking. 
 
 
Fig 4. The drug input characteristics with flat control and path tracking. 
 
Second, we show the simulation results for the linear 
controller defined in Section V. The saturation is chosen in 
order to get a suboptimal solution, i.e. the total amount of 
inhibitor used during the therapy is the lowest. This 
problem has already been explored in [2], where we 
presented, that if the tumor growth is initiated at the 
maximal value, then the optimal choice for the saturation is 
80 mg/kg/day. Fig. 5 shows the elimination of the tumor 
volume, and the drug input characteristics. The treatment is 
examined for 120 days. 
 
The speed of tumor volume elimination is nearly the same 
as in the case of flat control in Fig. 3; however, the drug 
input characteristics has some major differences. In the 
linear case in Fig. 5, the input is high at the beginning of 
the treatment (it is the achievable maximum if the 
saturation is present), and starts to decrease after around 3 
weeks, and then slowly decreases to the minimal value that 
is needed to maintain the avascular tumor state. 
 
The input characteristics in case of flat control however is 
much more desirable, since it yields sufficiently low drug 
doses even in absence of saturations, and the therapy is 
much more balanced. 
 
The total amount of inhibitor used in the linear case is 
2188.3 mg/kg for 120 days of treatment, which is lower 
than the value we got for the results with flat control that 
was only examined for 100 days. 
 
This is an advantage of the linear controller, but it is 
questionable, if its characteristics from therapeutic point of 
view are better than the result with flat control. 
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Fig. 5. The tumor volume evolution, and the drug input characteristics 
with the linear controller. 
 
 
VII. CONCLUSIONS 
 
We have examined the possibility of tumor therapy design 
with the use of control theory. Two different approaches 
were examined: path tracking based on exact linearization, 
and set point control based on working point linearization. 
Both approaches were successful in the sense that the 
tumor volume reached the lowest possible value, however 
their input characteristics was different. While the linear 
case resulted in a therapy that consumed fewer drug, the 
nonlinear controller resulted in much more balanced drug 
intake characteristics. 
 
Further work will be related to modern robust control 
methods, but also on the use of nonlinear control methods 
and other optimal control methods [19]. Higher order 
model synthesis will be also performed. A further aim of 
research is modeling and controlling combined therapy and 
validate it on animal experiments. 
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